John Sundy

John Sundy serves as the Chief Medical Officer and Head of R&D at Seismic Therapeutic since 2022 and holds an independent director position at Sanofi from April 2024. Additionally, John is a board member at Neutrolis Inc and CARRA, where John contributes to research for pediatric rheumatic diseases. Prior experience includes serving as Chief Medical Officer at Pandion Therapeutics, which was acquired by Merck in 2021, and holding senior roles in clinical research at Gilead Sciences. John has extensive academic experience, including directorial roles at the Duke Clinical Research Institute and a faculty position at Duke University Medical Center, where John focused on pulmonary and rheumatology medicine. John holds a Bachelor's Degree in Biology from Bucknell University and an MD, PhD in Medicine - Immunology from Hahnemann University School of Medicine.